Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Risk Reduction Behavior 1Prostatic Neoplasms 1Hot Flashes 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Estrogens, Conjugated (USP) × Clear all
NCT04821141 2025-10-29

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

Phase 2 Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Hot Flashes, Risk Reduction Behavior

NCT02729701 2022-03-09

Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

University of Kansas Medical Center

Phase 2 Completed
28 enrolled 9 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡